Trading Signals
Karyopharm Endometrial Cancer Trial Miss: What the SIENDO Failure Means for KPTI Stock
Karyopharm Therapeutics' selinexor-based trial in endometrial cancer has failed to hit its primary endpoint, delivering a sharp clinical setback that reshapes the company's near-term pipeline narrative. Here is what the data miss means for KPTI stock technically and fundamentally.